Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.

Notes: 

No survival benefit for postmenopausal, estrogen receptor (ER)-positive women with breast cancr using adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy. 5.5% had longer disease-free life.

TitleMeta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Publication TypeJournal Article
Year of Publication2001
AuthorsHartman AR, Fleming GF, Dillon JJ
JournalClinical breast cancer
Volume2
Issue2
Pagination138-43; discussion 144
Date Published2001 Jul
ISSN1526-8209
KeywordsAdult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival, Female, Fluorouracil, Follow-Up Studies, Humans, Lymph Nodes, Lymphatic Metastasis, Methotrexate, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Hormone-Dependent, Postmenopause, Receptors, Estrogen, Receptors, Progesterone, Survival Rate
Abstract

Conflicting results have been published regarding the efficacy of adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy in postmenopausal, estrogen receptor (ER)-positive women. The Oxford overview suggests real but limited benefit of any chemotherapy in this group of patients but avoids analyzing smaller subsets. We wished to better quantitate the benefit of adding CMF to tamoxifen in postmenopausal ER-positive women with tumor involvement of axillary lymph nodes. Six randomized studies comparing CMF plus tamoxifen to tomoxifen alone in postmenopausal, ER-positive, node-positive women have been published since 1992. They include 2368 patients. We performed a meta-analysis of 6 endpoints: survival, disease-free survival, locoregional recurrence, distant recurrence, contralateral breast recurrence, and thromboembolic complications. There was a statistically significant increase in disease-free survival from the addition of CMF-type chemotherapy to tamoxifen in this population; the absolute risk of relapse was reduced by 5.5% at 5 years. Effects of locoregional recurrence were greater than those on overall recurrence. No significant survival benefit was observed.

Alternate JournalClin. Breast Cancer
PubMed ID11899785
Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon
Get email updates
Recipes. upcoming classes.